Search

Your search keyword '"Maier F"' showing total 701 results
Start Over Author "Maier F"
701 results on '"Maier F"'

1. High-precision mass measurement of $^{103}$Sn restores smoothness of the mass surface

Author

Ireland, C. M., Maier, F. M., Bollen, G., Campbell, S. E., Chen, X., Erington, H., Gamage, N. D., Gutiérrez, M. J., Izzo, C., Leistenschneider, E., Lykiardopoulou, E. M., Orford, R., Porter, W. S., Puentes, D., Redshaw, M., Ringle, R., Rogers, S., Schwarz, S., Stackable, L., Sumithrarachchi, C. S., Valverde, A. A., Villari, A. C. C., and Yandow, I. T.

Subjects
Nuclear Experiment
Abstract

As a step towards the ultimate goal of a high-precision mass measurement of doubly-magic $^{100}$Sn, the mass of $^{103}$Sn was measured at the Low Energy Beam and Ion Trap (LEBIT) located at the Facility for Rare Isotope Beams (FRIB). Utilizing the time-of-flight ion cyclotron resonance (ToF-ICR) technique, a mass uncertainty of 3.7~keV was achieved, an improvement by more than an order of magnitude compared to a recent measurement performed in 2023 at the Cooler Storage Ring (CSRe) in Lanzhou. Although the LEBIT and CSRe mass measurements of $^{103}$Sn are in agreement, they diverge from the experimental mass value reported in the 2016 version of the Atomic Mass Evaluation (AME2016), which was derived from the measured $Q_{\beta^+}$ value and the mass of $^{103}$In. In AME2020, this indirectly measured $^{103}$Sn mass was classified as a `seriously irregular mass' and replaced with an extrapolated value, which aligns with the most recent measured values from CSRe and LEBIT. As such, the smoothness of the mass surface is confidently reestablished for $^{103}$Sn. Furthermore, LEBIT's mass measurement of $^{103}$Sn enabled a significant reduction in the mass uncertainties of five parent isotopes which are now dominated by uncertainties in their respective $Q$-values.

Published
2024

2. Gaussian Process-based prediction of memory performance and biomarker status in ageing and Alzheimer’s disease—A systematic model evaluation

Author

Nemali, A., Vockert, N., Berron, D., Maas, A., Bernal, J., Yakupov, R., Peters, O., Gref, D., Cosma, N., Preis, L., Priller, J., Spruth, E., Altenstein, S., Lohse, A., Fliessbach, K., Kimmich, O., Vogt, I., Wiltfang, J., Hansen, N., Bartels, C., Schott, B.H., Maier, F., Meiberth, D., Glanz, W., Incesoy, E., Butryn, M., Buerger, K., Janowitz, D., Pernecky, R., Rauchmann, B., Burow, L., Teipel, S., Kilimann, I., Göerß, D., Dyrba, M., Laske, C., Munk, M., Sanzenbacher, C., Müller, S., Spottke, A., Roy, N., Heneka, M., Brosseron, F., Roeske, S., Dobisch, L., Ramirez, A., Ewers, M., Dechent, P., Scheffler, K., Kleineidam, L., Wolfsgruber, S., Wagner, M., Jessen, F., Duzel, E., and Ziegler, G.

Published
2023
Full Text
View/download PDF

9. Temperature and ambient atmosphere dependent electrical characterization of sputtered IrO2/TiO2/IrO2 capacitors.

Author

Maier, F. J., Schneider, M., Artemenko, A., Kromka, A., Stöger-Pollach, M., and Schmid, U.

Subjects
*ELECTRIC charge, *MEMRISTORS, *CAPACITORS, *IRIDIUM oxide, *OXYGEN evolution reactions, *FLEXOELECTRICITY, *TITANIUM dioxide nanoparticles
Abstract

Titanium dioxide (TiO2) is a high-performance material for emerging device applications, such as in resistive switching memories, in high-k capacitors, or, due to its flexoelectricity, in micro/nano-electro-mechanical systems. Enhanced electrical properties of TiO2 are ensured, especially by a careful selection of the bottom electrode material. Iridium dioxide (IrO2) is an excellent choice, as it favors the high-k rutile phase growth of TiO2. In this study, we introduce the fabrication of IrO2/TiO2/IrO2 capacitors and thoroughly characterize their electrical behavior. These capacitors show a dielectric constant for low temperature sputtered TiO2 of ∼70. From leakage current measurements, a coupled capacitive–memristive behavior is determined, which is assumed due to the presence of a reduced TiO2−x layer at the IrO2/TiO2 interface observed from transmission electron microscopy analyses. The memristive effect most probably originates from trapping and detrapping of electric charges in oxygen vacancy defects, which themselves can be generated and annihilated through an applied electric field, subsequently changing the resistance of the capacitor. The electric degradation type is identified as a filament-forming mechanism. Additionally, the temperature dependence of the leakage current is measured, demonstrating that the temperature behavior is strongly influenced by the ambient atmosphere. The latter dependency leads to the hypothesis that the oxygen evolution reaction of water incorporated in the IrO2/TiO2 interface passivates vacancies, thus significantly impacting the vacancy density in TiO2 and, as a further consequence, the electrical performance. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

13. α-phase PVDF MEMS cantilever excited by electrostriction and evaluated up to 160 °C in air by laser-Doppler vibrometry.

Author

Maier, F. J., Schneider, M., Ullmann, P., Hafner, J., and Schmid, U.

Subjects
*CANTILEVERS, *ELECTROSTRICTION, *CONDUCTING polymers, *SMART materials, *POLYVINYLIDENE fluoride, *QUALITY factor, *ELECTROCHROMIC windows
Abstract

The electroactive polymer polyvinylidene fluoride (PVDF) has gained much interest in smart materials research with a wide application range for industry and consumer applications due to the low cost, flexibility, chemical resistance, non-toxicity, and light weight. In this work, we present an α-phase PVDF cantilever that exploits electrostriction as the main transducer mechanism for excitation. We realize thin PVDF films with a thickness of ∼190 nm and a low roughness (∼19 nm RMS). Electrostrictive cantilevers need high electric fields to achieve amplitudes comparable to piezoelectric counterparts. At thinner films, lower voltage levels are requested for comparable electric fields, thus making electrostrictive PVDF cantilevers a viable route and subsequently allowing broader use of PVDF in MEMS devices. We use an asymmetric electrode design that has the advantage of shifting the neutral axis out of the PVDF without enhancing cantilever thickness with a supporting device layer. In addition, these devices can be produced by CMOS compatible micromachining techniques. We measured the electrostrictive and piezoelectric actuation signal with laser-Doppler vibrometry and showed the frequency spectrum and curvature of such α-phase PVDF cantilevers. The cantilevers have a curvate of up to 120 m−1 at 1500 kV/cm. We demonstrate that the electrostrictive actuation has a low temperature dependency in the range from 25 up to 130 °C. A typical cantilever exhibits a geometry dependent low spring constant (k ∼ 0.3 N m−1) and a low quality factor (Q ∼ 75) in air. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

16. Doppler and sympathetic cooling for the investigation of short-lived radioactive ions

Author

Sels, S., primary, Maier, F. M., additional, Au, M., additional, Fischer, P., additional, Kanitz, C., additional, Lagaki, V., additional, Lechner, S., additional, Leistenschneider, E., additional, Leimbach, D., additional, Lykiardopoulou, E. M., additional, Kwiatkowski, A. A., additional, Manovitz, T., additional, Vila Gracia, Y. N., additional, Neyens, G., additional, Plattner, P., additional, Rothe, S., additional, Schweikhard, L., additional, Vilen, M., additional, Wolf, R. N., additional, and Malbrunot-Ettenauer, S., additional

Published
2022
Full Text
View/download PDF

19. Robotic Systems for MR-Guided Interventions

Author

Bock, M., Krafft, A., Maier, F., Umathum, R., Homagk, A. -K., Alt, S., Zhang, K., Pitsaer, C., Jenne, J., Semmler, W., Magjarevic, Ratko, editor, Dössel, Olaf, editor, and Schlegel, Wolfgang C., editor

Published
2009
Full Text
View/download PDF

25. Outcomes of Cerebral Venous Thrombosis due to Vaccine-Induced Immune Thrombotic Thrombocytopenia After the Acute Phase

Author

Munckhof, A. van de, Lindgren, E., Kleinig, T.J., Field, T.S., Cordonnier, C., Krzywicka, K., Poli, S., Sanchez van Kammen, M., Borhani-Haghighi, A., Lemmens, R., Scutelnic, A., Ciccone, A., Gattringer, T., Wittstock, M., Dizonno, V., Devroye, A., Elkady, A., Günther, A., Cervera, A., Mengel, A., Chew, B.L.A., Buck, B., Zanferrari, C., Garcia-Esperon, C., Jacobi, C., Soriano, C., Michalski, D., Zamani, Z., Blacquiere, D., Johansson, E., Cuadrado-Godia, E., Vuillier, F., Bode, F.J., Caparros, F., Maier, F., Tsivgoulis, G., Katzberg, H.D., Duan, J., Burrow, J., Pelz, J., Mbroh, J., Oen, J., Schouten, J., Zimmermann, J., Ng, K., Garambois, K., Petruzzellis, M., Dias, M., Ghiasian, M., Romoli, M., Miranda, M., Wronski, M., Skjelland, M., Almasi-Dooghaee, M., Cuisenier, P., Murphy, S., Timsit, S., Coutts, S.B., Schönenberger, S., Nagel, S., Hiltunen, S., Chatterton, S., Cox, T., Bartsch, T., Shaygannejad, V., Mirzaasgari, Z., Middeldorp, S., Levi, M.M., Kremer Hovinga, J.A., Jood, K., Tatlisumak, T., Putaala, J., Heldner, M.R., Arnold, M., Aguiar de Sousa, D., Ferro, J.M., Coutinho, J.M., Munckhof, A. van de, Lindgren, E., Kleinig, T.J., Field, T.S., Cordonnier, C., Krzywicka, K., Poli, S., Sanchez van Kammen, M., Borhani-Haghighi, A., Lemmens, R., Scutelnic, A., Ciccone, A., Gattringer, T., Wittstock, M., Dizonno, V., Devroye, A., Elkady, A., Günther, A., Cervera, A., Mengel, A., Chew, B.L.A., Buck, B., Zanferrari, C., Garcia-Esperon, C., Jacobi, C., Soriano, C., Michalski, D., Zamani, Z., Blacquiere, D., Johansson, E., Cuadrado-Godia, E., Vuillier, F., Bode, F.J., Caparros, F., Maier, F., Tsivgoulis, G., Katzberg, H.D., Duan, J., Burrow, J., Pelz, J., Mbroh, J., Oen, J., Schouten, J., Zimmermann, J., Ng, K., Garambois, K., Petruzzellis, M., Dias, M., Ghiasian, M., Romoli, M., Miranda, M., Wronski, M., Skjelland, M., Almasi-Dooghaee, M., Cuisenier, P., Murphy, S., Timsit, S., Coutts, S.B., Schönenberger, S., Nagel, S., Hiltunen, S., Chatterton, S., Cox, T., Bartsch, T., Shaygannejad, V., Mirzaasgari, Z., Middeldorp, S., Levi, M.M., Kremer Hovinga, J.A., Jood, K., Tatlisumak, T., Putaala, J., Heldner, M.R., Arnold, M., Aguiar de Sousa, D., Ferro, J.M., and Coutinho, J.M.

Abstract

Item does not contain fulltext, BACKGROUND: Cerebral venous thrombosis (CVT) due to vaccine-induced immune thrombotic thrombocytopenia (VITT) is a severe condition, with high in-hospital mortality rates. Here, we report clinical outcomes of patients with CVT-VITT after SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination who survived initial hospitalization. METHODS: We used data from an international registry of patients who developed CVT within 28 days of SARS-CoV-2 vaccination, collected until February 10, 2022. VITT diagnosis was classified based on the Pavord criteria. Outcomes were mortality, functional independence (modified Rankin Scale score 0-2), VITT relapse, new thrombosis, and bleeding events (all after discharge from initial hospitalization). RESULTS: Of 107 CVT-VITT cases, 43 (40%) died during initial hospitalization. Of the remaining 64 patients, follow-up data were available for 60 (94%) patients (37 definite VITT, 9 probable VITT, and 14 possible VITT). Median age was 40 years and 45/60 (75%) patients were women. Median follow-up time was 150 days (interquartile range, 94-194). Two patients died during follow-up (3% [95% CI, 1%-11%). Functional independence was achieved by 53/60 (88% [95% CI, 78%-94%]) patients. No new venous or arterial thrombotic events were reported. One patient developed a major bleeding during follow-up (fatal intracerebral bleed). CONCLUSIONS: In contrast to the high mortality of CVT-VITT in the acute phase, mortality among patients who survived the initial hospitalization was low, new thrombotic events did not occur, and bleeding events were rare. Approximately 9 out of 10 CVT-VITT patients who survived the acute phase were functionally independent at follow-up.

Published
2022

26. Management of Cerebral Venous Thrombosis Due to Adenoviral COVID-19 Vaccination

Author

Scutelnic, A., Krzywicka, K., Mbroh, J., Munckhof, A. van de, Kammen, M.S.V., Sousa, D.A. de, Lindgren, E., Jood, K., Günther, A., Hiltunen, S., Putaala, J., Tiede, A., Maier, F., Kern, R., Bartsch, T., Althaus, K., Ciccone, A., Wiedmann, M., Skjelland, M., Medina, A., Cuadrado-Godia, E., Cox, T., Aujayeb, A., Raposo, N., Garambois, K., Payen, J.F., Vuillier, F., Franchineau, G., Timsit, S., Bougon, D., Dubois, M.C., Tawa, A., Tracol, C., Maistre, E. De, Bonneville, F., Vayne, C., Mengel, A., Michalski, D., Pelz, J., Wittstock, M., Bode, F., Zimmermann, J., Schouten, J., Buture, A., Murphy, S., Palma, V., Negro, A., Gutschalk, A., Nagel, S., Schoenenberger, S., Frisullo, G., Zanferrari, C., Grillo, F., Giammello, F., Martin, M.M., Cervera, A., Burrow, J., Esperon, C.G., Chew, B.L.A., Kleinig, T.J., Soriano, C., Zimatore, D.S., Petruzzellis, M., Elkady, A., Miranda, M.S., Fernandes, J., Vogel, A., Johansson, E., Philip, A.P., Coutts, S.B., Bal, S., Buck, B., Legault, C., Blacquiere, D., Katzberg, H.D., Field, T.S., Dizonno, V., Gattringer, T., Jacobi, C., Devroye, A., Lemmens, R., Kristoffersen, E.S., Poggio, M.B. di, Ghiasian, M., Karapanayiotides, T., Chatterton, S., Wronski, M., Ng, K., Kahnis, R., Geeraerts, T., Reiner, P., Cordonnier, C., Middeldorp, S., Levi, M., Gorp, E.C. van, Beek, D van, Brodard, J., Kremer Hovinga, J.A., Kruip, M., Tatlisumak, T., Poli, S., Heldner, M.R., Scutelnic, A., Krzywicka, K., Mbroh, J., Munckhof, A. van de, Kammen, M.S.V., Sousa, D.A. de, Lindgren, E., Jood, K., Günther, A., Hiltunen, S., Putaala, J., Tiede, A., Maier, F., Kern, R., Bartsch, T., Althaus, K., Ciccone, A., Wiedmann, M., Skjelland, M., Medina, A., Cuadrado-Godia, E., Cox, T., Aujayeb, A., Raposo, N., Garambois, K., Payen, J.F., Vuillier, F., Franchineau, G., Timsit, S., Bougon, D., Dubois, M.C., Tawa, A., Tracol, C., Maistre, E. De, Bonneville, F., Vayne, C., Mengel, A., Michalski, D., Pelz, J., Wittstock, M., Bode, F., Zimmermann, J., Schouten, J., Buture, A., Murphy, S., Palma, V., Negro, A., Gutschalk, A., Nagel, S., Schoenenberger, S., Frisullo, G., Zanferrari, C., Grillo, F., Giammello, F., Martin, M.M., Cervera, A., Burrow, J., Esperon, C.G., Chew, B.L.A., Kleinig, T.J., Soriano, C., Zimatore, D.S., Petruzzellis, M., Elkady, A., Miranda, M.S., Fernandes, J., Vogel, A., Johansson, E., Philip, A.P., Coutts, S.B., Bal, S., Buck, B., Legault, C., Blacquiere, D., Katzberg, H.D., Field, T.S., Dizonno, V., Gattringer, T., Jacobi, C., Devroye, A., Lemmens, R., Kristoffersen, E.S., Poggio, M.B. di, Ghiasian, M., Karapanayiotides, T., Chatterton, S., Wronski, M., Ng, K., Kahnis, R., Geeraerts, T., Reiner, P., Cordonnier, C., Middeldorp, S., Levi, M., Gorp, E.C. van, Beek, D van, Brodard, J., Kremer Hovinga, J.A., Kruip, M., Tatlisumak, T., Poli, S., and Heldner, M.R.

Abstract

Contains fulltext : 282309.pdf (Publisher’s version ) (Open Access), OBJECTIVE: Cerebral venous thrombosis (CVT) caused by vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare adverse effect of adenovirus-based severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccines. In March 2021, after autoimmune pathogenesis of VITT was discovered, treatment recommendations were developed. These comprised immunomodulation, non-heparin anticoagulants, and avoidance of platelet transfusion. The aim of this study was to evaluate adherence to these recommendations and its association with mortality. METHODS: We used data from an international prospective registry of patients with CVT after the adenovirus-based SARS-CoV-2 vaccination. We analyzed possible, probable, or definite VITT-CVT cases included until January 18, 2022. Immunomodulation entailed administration of intravenous immunoglobulins and/or plasmapheresis. RESULTS: Ninety-nine patients with VITT-CVT from 71 hospitals in 17 countries were analyzed. Five of 38 (13%), 11 of 24 (46%), and 28 of 37 (76%) of the patients diagnosed in March, April, and from May onward, respectively, were treated in-line with VITT recommendations (p < 0.001). Overall, treatment according to recommendations had no statistically significant influence on mortality (14/44 [32%] vs 29/55 [52%], adjusted odds ratio [OR] = 0.43, 95% confidence interval [CI] = 0.16-1.19). However, patients who received immunomodulation had lower mortality (19/65 [29%] vs 24/34 [70%], adjusted OR = 0.19, 95% CI = 0.06-0.58). Treatment with non-heparin anticoagulants instead of heparins was not associated with lower mortality (17/51 [33%] vs 13/35 [37%], adjusted OR = 0.70, 95% CI = 0.24-2.04). Mortality was also not significantly influenced by platelet transfusion (17/27 [63%] vs 26/72 [36%], adjusted OR = 2.19, 95% CI = 0.74-6.54). CONCLUSIONS: In patients with VITT-CVT, adherence to VITT treatment recommendations improved over time. Immunomodulation seems crucial for reducing mortality of VITT-CVT. ANN NEUROL

Published
2022

34. Condensation

Author

Maier, F. J. and Babbitt, H. E.

Published
1954

35. Condensation

Author

Noble, R. E., Babbitt, H. E., and Maier, F. J.

Published
1954

36. Condensation

Author

Maier, F. J., Straub, Conrad P., Thompson, R. E., and Babbitt, H. E.

Published
1953

37. Condensation

Author

Babbitt, H. E., Maier, F. J., and Thompson, R. E.

Published
1953

39. Condensation

Author

Rudolfs, W., Albanese, M., Babbitt, H. E., Maier, F. J., and Mueller, K.

Published
1951

40. Condensation

Author

Thompson, R. E., Maier, F. J., and Babbitt, H. E.

Published
1951

41. Condensation

Author

Babbitt, H. E., Rudolfs, W., Albanese, M., and Maier, F. J.

Published
1952

42. Condensation

Author

Maier, F. J., Babbitt, H. E., and Rudolfs, W.

Published
1952

43. Condensation

Author

Hirsch, A. A., Rudolfs, Willem, Thompson, R. E., Babbitt, H. E., Straub, Conrad P., and Maier, F. J.

Published
1950

45. Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia

Author

Sanchez van Kammen, M., Aguiar de Sousa, D., Poli, S., Cordonnier, C., Heldner, M.R., Munckhof, A. van de, Krzywicka, K., Haaps, T. van, Ciccone, A., Middeldorp, S., Levi, M.M., Hovinga, J.A. Kremer, Silvis, S., Hiltunen, S., Mansour, M., Arauz, A., Barboza, M.A., Field, T.S., Tsivgoulis, G., Nagel, S., Lindgren, E., Tatlisumak, T., Jood, K., Putaala, J., Ferro, J.M., Arnold, M., Coutinho, J.M., Sharma, A.R., Elkady, A., Negro, A., Günther, A., Gutschalk, A., Schönenberger, S., Buture, A., Murphy, S., Nunes, A., Tiede, A., Philip, A. Puthuppallil, Mengel, A., Medina, A., Vogel, Å. Hellström, Tawa, A., Aujayeb, A., Casolla, B., Buck, B., Zanferrari, C., Garcia-Esperon, C., Vayne, C., Legault, C., Pfrepper, C., Tracol, C., Soriano, C., Guisado-Alonso, D., Bougon, D., Zimatore, D.S., Michalski, D., Blacquiere, D., Johansson, E., Cuadrado-Godia, E., Maistre, E. De, Carrera, E., Vuillier, F., Bonneville, F., Giammello, F., Bode, F.J., Zimmerman, J., d'Onofrio, F., Grillo, F., Cotton, F., Caparros, F., Puy, L., Maier, F., Gulli, G., Frisullo, G., Polkinghorne, G., Franchineau, G., Cangür, H., Katzberg, H., Sibon, I., Baharoglu, I., Brar, J., Payen, J.F., Burrow, J., Fernandes, J., Schouten, J., Althaus, K., Garambois, K., Derex, L., Humbertjean, L., Hernandez, L. Herrera, Kellermair, L., Martin, M, Petruzzellis, M., Cotelli, M., Dubois, M.C., Carvalho, M., Wittstock, M., Miranda, M., Skjelland, M., Poggio, M., et al. Bandettini di, Sanchez van Kammen, M., Aguiar de Sousa, D., Poli, S., Cordonnier, C., Heldner, M.R., Munckhof, A. van de, Krzywicka, K., Haaps, T. van, Ciccone, A., Middeldorp, S., Levi, M.M., Hovinga, J.A. Kremer, Silvis, S., Hiltunen, S., Mansour, M., Arauz, A., Barboza, M.A., Field, T.S., Tsivgoulis, G., Nagel, S., Lindgren, E., Tatlisumak, T., Jood, K., Putaala, J., Ferro, J.M., Arnold, M., Coutinho, J.M., Sharma, A.R., Elkady, A., Negro, A., Günther, A., Gutschalk, A., Schönenberger, S., Buture, A., Murphy, S., Nunes, A., Tiede, A., Philip, A. Puthuppallil, Mengel, A., Medina, A., Vogel, Å. Hellström, Tawa, A., Aujayeb, A., Casolla, B., Buck, B., Zanferrari, C., Garcia-Esperon, C., Vayne, C., Legault, C., Pfrepper, C., Tracol, C., Soriano, C., Guisado-Alonso, D., Bougon, D., Zimatore, D.S., Michalski, D., Blacquiere, D., Johansson, E., Cuadrado-Godia, E., Maistre, E. De, Carrera, E., Vuillier, F., Bonneville, F., Giammello, F., Bode, F.J., Zimmerman, J., d'Onofrio, F., Grillo, F., Cotton, F., Caparros, F., Puy, L., Maier, F., Gulli, G., Frisullo, G., Polkinghorne, G., Franchineau, G., Cangür, H., Katzberg, H., Sibon, I., Baharoglu, I., Brar, J., Payen, J.F., Burrow, J., Fernandes, J., Schouten, J., Althaus, K., Garambois, K., Derex, L., Humbertjean, L., Hernandez, L. Herrera, Kellermair, L., Martin, M, Petruzzellis, M., Cotelli, M., Dubois, M.C., Carvalho, M., Wittstock, M., Miranda, M., Skjelland, M., and Poggio, M., et al. Bandettini di

Abstract

Item does not contain fulltext, IMPORTANCE: Thrombosis with thrombocytopenia syndrome (TTS) has been reported after vaccination with the SARS-CoV-2 vaccines ChAdOx1 nCov-19 (Oxford-AstraZeneca) and Ad26.COV2.S (Janssen/Johnson & Johnson). OBJECTIVE: To describe the clinical characteristics and outcome of patients with cerebral venous sinus thrombosis (CVST) after SARS-CoV-2 vaccination with and without TTS. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data from an international registry of consecutive patients with CVST within 28 days of SARS-CoV-2 vaccination included between March 29 and June 18, 2021, from 81 hospitals in 19 countries. For reference, data from patients with CVST between 2015 and 2018 were derived from an existing international registry. Clinical characteristics and mortality rate were described for adults with (1) CVST in the setting of SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia, (2) CVST after SARS-CoV-2 vaccination not fulling criteria for TTS, and (3) CVST unrelated to SARS-CoV-2 vaccination. EXPOSURES: Patients were classified as having TTS if they had new-onset thrombocytopenia without recent exposure to heparin, in accordance with the Brighton Collaboration interim criteria. MAIN OUTCOMES AND MEASURES: Clinical characteristics and mortality rate. RESULTS: Of 116 patients with postvaccination CVST, 78 (67.2%) had TTS, of whom 76 had been vaccinated with ChAdOx1 nCov-19; 38 (32.8%) had no indication of TTS. The control group included 207 patients with CVST before the COVID-19 pandemic. A total of 63 of 78 (81%), 30 of 38 (79%), and 145 of 207 (70.0%) patients, respectively, were female, and the mean (SD) age was 45 (14), 55 (20), and 42 (16) years, respectively. Concomitant thromboembolism occurred in 25 of 70 patients (36%) in the TTS group, 2 of 35 (6%) in the no TTS group, and 10 of 206 (4.9%) in the control group, and in-hospital mortality rates were 47% (36 of 76; 95% CI, 37-58), 5% (2 of 37; 95% CI, 1-18), and 3.9% (8 of 207; 95% CI, 2.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results